儿童复发急性淋巴细胞白血病的治疗策略
儿童复发急性淋巴细胞白血病治疗困难,首次复发仅约50%长期生存,二次及以后复发更差。诊断3年内复发及任何T-ALL复发尤其难治。近十年免疫治疗改变了治疗格局,当前研究聚焦免疫治疗整合、长期生存与副作用及替代造血干细胞移植的时机,并探索分子靶向治疗。
要点
- 首次复发ALL仅约50%儿童获得长期生存,二次及以后复发结局更差。
- 诊断3年内复发及任何T-ALL复发尤其难以挽救。
- 近十年免疫治疗改变了复发ALL治疗格局,研究聚焦其整合与替代HSCT时机。
核心结论
- 儿童复发ALL治疗仍具挑战,生存率远低于初诊,首次复发仅约50%长期生存,二次及以后复发更差。
- 诊断3年内复发及任何T-ALL复发尤其难以挽救。
- 近十年免疫治疗改变了治疗格局,当前研究聚焦免疫治疗整合、长期生存与副作用及替代HSCT时机,分子靶向治疗是活跃研究方向。
- 这些进展为儿童复发ALL提供了毒性更低、更有效治疗的希望。
研究设计与样本
- 综述类文章,检索范围原文未报告。
主要发现
- 首次复发ALL仅约50%儿童获得长期生存,第二次或更晚复发结局更差。
- 诊断3年内复发及任何T-ALL复发尤其难以挽救。
- 直至近期,治疗选择限于强化细胞毒化疗联合或不联合局部放疗及异基因造血干细胞移植(HSCT)。
- 近十年多种有前景的免疫治疗药物被开发,改变了儿童复发ALL的治疗格局。
- 通过全面基因组分析对复发生物学认识增加,分子靶向治疗的整合是活跃研究领域。
关键数值与推荐
- 首次复发ALL长期生存率约50%。
- 诊断3年内复发及任何T-ALL复发尤其难以挽救。
临床怎么用
- 原文通过多个病例展示当代治疗决策,未给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children, with survival rates lagging well behind those observed at initial diagnosis. Although there have been some improvements in outcomes over the past few decades, only ∼50% of children with first relapse of ALL survive long term, and outcomes are much worse with second or later relapses. Recurrences that occur within 3 years of diagnosis and any T-ALL relapses are particularly difficult to salvage. Until recently, treatment options were limited to intensive cytotoxic chemotherapy with or without site-directed radiotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). In the past decade, several promising immunotherapeutics have been developed, changing the treatment landscape for children with relapsed ALL. Current research in this field is focusing on how to best incorporate immunotherapeutics into salvage regimens and investigate long-term survival and side effects, and when these might replace HSCT. As more knowledge is gained about the biology of relapse through comprehensive genomic profiling, incorporation of molecularly targeted therapies is another area of active investigation. These advances in treatment offer real promise for less toxic and more effective therapy for children with relapsed ALL, and we present several cases highlighting contemporary treatment decision-making.
引用
- Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood. 2020. PMID: 32589723. doi:10.1182/blood.2019004043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。